Lonza Group AG
Lonza Group AG (LZAGF) Stock Competitors & Peer Comparison
See (LZAGF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LZAGF | $635.20 | -2.91% | 44.7B | 38.29 | $16.61 | +0.37% |
| LZAGY | $63.19 | -2.89% | 44.8B | 37.94 | $1.66 | +0.67% |
| WUXAY | $15.60 | +1.68% | 44.6B | 16.08 | $0.97 | +1.20% |
| WUXIF | $13.88 | +0.00% | 41.4B | 14.31 | $0.97 | +1.68% |
| ERFSF | $73.92 | +0.13% | 12.7B | 24.15 | $3.01 | +0.83% |
| BMXMF | $105.41 | +0.00% | 12.4B | 26.75 | $3.94 | +0.89% |
| SKHHY | $14.27 | -0.28% | 7.1B | 18.27 | $0.79 | +2.24% |
| SKHCF | $14.58 | +4.14% | 7.1B | 18.10 | $0.79 | +2.18% |
| HNGZY | $4.00 | +0.00% | 6.2B | 26.67 | $0.15 | +0.72% |
| DSRLF | $71.94 | +0.00% | 3.9B | 21.47 | $3.35 | +1.88% |
Stock Comparison
LZAGF vs LZAGY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, LZAGY has a market cap of 44.8B. Regarding current trading prices, LZAGF is priced at $635.20, while LZAGY trades at $63.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas LZAGY's P/E ratio is 37.94. In terms of profitability, LZAGF's ROE is +0.10%, compared to LZAGY's ROE of +0.10%. Regarding short-term risk, LZAGF is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check LZAGY's competition here
LZAGF vs WUXAY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, WUXAY has a market cap of 44.6B. Regarding current trading prices, LZAGF is priced at $635.20, while WUXAY trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas WUXAY's P/E ratio is 16.08. In terms of profitability, LZAGF's ROE is +0.10%, compared to WUXAY's ROE of +0.28%. Regarding short-term risk, LZAGF is more volatile compared to WUXAY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check WUXAY's competition here
LZAGF vs WUXIF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, WUXIF has a market cap of 41.4B. Regarding current trading prices, LZAGF is priced at $635.20, while WUXIF trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas WUXIF's P/E ratio is 14.31. In terms of profitability, LZAGF's ROE is +0.10%, compared to WUXIF's ROE of +0.28%. Regarding short-term risk, LZAGF is less volatile compared to WUXIF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check WUXIF's competition here
LZAGF vs ERFSF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ERFSF has a market cap of 12.7B. Regarding current trading prices, LZAGF is priced at $635.20, while ERFSF trades at $73.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ERFSF's P/E ratio is 24.15. In terms of profitability, LZAGF's ROE is +0.10%, compared to ERFSF's ROE of +0.12%. Regarding short-term risk, LZAGF is more volatile compared to ERFSF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ERFSF's competition here
LZAGF vs BMXMF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BMXMF has a market cap of 12.4B. Regarding current trading prices, LZAGF is priced at $635.20, while BMXMF trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BMXMF's P/E ratio is 26.75. In terms of profitability, LZAGF's ROE is +0.10%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, LZAGF is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check BMXMF's competition here
LZAGF vs SKHHY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SKHHY has a market cap of 7.1B. Regarding current trading prices, LZAGF is priced at $635.20, while SKHHY trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SKHHY's P/E ratio is 18.27. In terms of profitability, LZAGF's ROE is +0.10%, compared to SKHHY's ROE of +0.05%. Regarding short-term risk, LZAGF is more volatile compared to SKHHY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SKHHY's competition here
LZAGF vs SKHCF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SKHCF has a market cap of 7.1B. Regarding current trading prices, LZAGF is priced at $635.20, while SKHCF trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SKHCF's P/E ratio is 18.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to SKHCF's ROE of +0.06%. Regarding short-term risk, LZAGF is more volatile compared to SKHCF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SKHCF's competition here
LZAGF vs HNGZY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, HNGZY has a market cap of 6.2B. Regarding current trading prices, LZAGF is priced at $635.20, while HNGZY trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to HNGZY's ROE of +0.04%. Regarding short-term risk, LZAGF is less volatile compared to HNGZY. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check HNGZY's competition here
LZAGF vs DSRLF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, DSRLF has a market cap of 3.9B. Regarding current trading prices, LZAGF is priced at $635.20, while DSRLF trades at $71.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas DSRLF's P/E ratio is 21.47. In terms of profitability, LZAGF's ROE is +0.10%, compared to DSRLF's ROE of +0.12%. Regarding short-term risk, LZAGF is less volatile compared to DSRLF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check DSRLF's competition here
LZAGF vs VIMGF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, VIMGF has a market cap of 1.5B. Regarding current trading prices, LZAGF is priced at $635.20, while VIMGF trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas VIMGF's P/E ratio is 39.57. In terms of profitability, LZAGF's ROE is +0.10%, compared to VIMGF's ROE of +0.05%. Regarding short-term risk, LZAGF is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check VIMGF's competition here
LZAGF vs GNTLF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, GNTLF has a market cap of 1.3B. Regarding current trading prices, LZAGF is priced at $635.20, while GNTLF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to GNTLF's ROE of -1.85%. Regarding short-term risk, LZAGF is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check GNTLF's competition here
LZAGF vs MRCHF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MRCHF has a market cap of 1.1B. Regarding current trading prices, LZAGF is priced at $635.20, while MRCHF trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MRCHF's P/E ratio is 44.29. In terms of profitability, LZAGF's ROE is +0.10%, compared to MRCHF's ROE of +0.04%. Regarding short-term risk, LZAGF is less volatile compared to MRCHF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check MRCHF's competition here
LZAGF vs IDGXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IDGXF has a market cap of 372M. Regarding current trading prices, LZAGF is priced at $635.20, while IDGXF trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IDGXF's P/E ratio is 16.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDGXF's ROE of +0.28%. Regarding short-term risk, LZAGF is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IDGXF's competition here
LZAGF vs EDTXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, EDTXF has a market cap of 297.8M. Regarding current trading prices, LZAGF is priced at $635.20, while EDTXF trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas EDTXF's P/E ratio is -8.46. In terms of profitability, LZAGF's ROE is +0.10%, compared to EDTXF's ROE of +0.88%. Regarding short-term risk, LZAGF is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EDTXF's competition here
LZAGF vs AMCY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, AMCY has a market cap of 171.3M. Regarding current trading prices, LZAGF is priced at $635.20, while AMCY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas AMCY's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to AMCY's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check AMCY's competition here
LZAGF vs NNGRF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, NNGRF has a market cap of 164.3M. Regarding current trading prices, LZAGF is priced at $635.20, while NNGRF trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, LZAGF's ROE is +0.10%, compared to NNGRF's ROE of -0.05%. Regarding short-term risk, LZAGF is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check NNGRF's competition here
LZAGF vs DIUXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, DIUXF has a market cap of 141.3M. Regarding current trading prices, LZAGF is priced at $635.20, while DIUXF trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas DIUXF's P/E ratio is -83.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to DIUXF's ROE of -0.04%. Regarding short-term risk, LZAGF is less volatile compared to DIUXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check DIUXF's competition here
LZAGF vs CORBF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, CORBF has a market cap of 127.3M. Regarding current trading prices, LZAGF is priced at $635.20, while CORBF trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas CORBF's P/E ratio is 2.72. In terms of profitability, LZAGF's ROE is +0.10%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CORBF's competition here
LZAGF vs LDXHF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, LDXHF has a market cap of 99.2M. Regarding current trading prices, LZAGF is priced at $635.20, while LDXHF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas LDXHF's P/E ratio is -13.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to LDXHF's ROE of -1.21%. Regarding short-term risk, LZAGF is more volatile compared to LDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check LDXHF's competition here
LZAGF vs THOXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, THOXF has a market cap of 73.8M. Regarding current trading prices, LZAGF is priced at $635.20, while THOXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas THOXF's P/E ratio is -7.45. In terms of profitability, LZAGF's ROE is +0.10%, compared to THOXF's ROE of -1.67%. Regarding short-term risk, LZAGF is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check THOXF's competition here
LZAGF vs TIHE Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, TIHE has a market cap of 71.9M. Regarding current trading prices, LZAGF is priced at $635.20, while TIHE trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas TIHE's P/E ratio is 0.32. In terms of profitability, LZAGF's ROE is +0.10%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, LZAGF is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TIHE's competition here
LZAGF vs PFGTF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, PFGTF has a market cap of 69.8M. Regarding current trading prices, LZAGF is priced at $635.20, while PFGTF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas PFGTF's P/E ratio is -3.41. In terms of profitability, LZAGF's ROE is +0.10%, compared to PFGTF's ROE of -1.30%. Regarding short-term risk, LZAGF is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check PFGTF's competition here
LZAGF vs BIOGF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BIOGF has a market cap of 65.4M. Regarding current trading prices, LZAGF is priced at $635.20, while BIOGF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, LZAGF is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOGF's competition here
LZAGF vs PCNEF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, PCNEF has a market cap of 62M. Regarding current trading prices, LZAGF is priced at $635.20, while PCNEF trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, LZAGF's ROE is +0.10%, compared to PCNEF's ROE of -0.05%. Regarding short-term risk, LZAGF is less volatile compared to PCNEF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check PCNEF's competition here
LZAGF vs BMKDF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BMKDF has a market cap of 44.5M. Regarding current trading prices, LZAGF is priced at $635.20, while BMKDF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BMKDF's P/E ratio is -42.38. In terms of profitability, LZAGF's ROE is +0.10%, compared to BMKDF's ROE of -1.53%. Regarding short-term risk, LZAGF is more volatile compared to BMKDF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BMKDF's competition here
LZAGF vs BIOQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BIOQ has a market cap of 33.5M. Regarding current trading prices, LZAGF is priced at $635.20, while BIOQ trades at $37.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BIOQ's P/E ratio is 15.83. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOQ's ROE of +0.01%. Regarding short-term risk, LZAGF is more volatile compared to BIOQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOQ's competition here
LZAGF vs SNANF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SNANF has a market cap of 25.3M. Regarding current trading prices, LZAGF is priced at $635.20, while SNANF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SNANF's P/E ratio is -11.07. In terms of profitability, LZAGF's ROE is +0.10%, compared to SNANF's ROE of -10.44%. Regarding short-term risk, LZAGF is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SNANF's competition here
LZAGF vs ANPCY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ANPCY has a market cap of 22M. Regarding current trading prices, LZAGF is priced at $635.20, while ANPCY trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ANPCY's P/E ratio is -0.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to ANPCY's ROE of -0.90%. Regarding short-term risk, LZAGF is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ANPCY's competition here
LZAGF vs PCHM Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, PCHM has a market cap of 22M. Regarding current trading prices, LZAGF is priced at $635.20, while PCHM trades at $3.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas PCHM's P/E ratio is -0.02. In terms of profitability, LZAGF's ROE is +0.10%, compared to PCHM's ROE of +0.25%. Regarding short-term risk, LZAGF is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check PCHM's competition here
LZAGF vs VILGF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, VILGF has a market cap of 20.7M. Regarding current trading prices, LZAGF is priced at $635.20, while VILGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas VILGF's P/E ratio is -0.30. In terms of profitability, LZAGF's ROE is +0.10%, compared to VILGF's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check VILGF's competition here
LZAGF vs CLIFF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, CLIFF has a market cap of 18M. Regarding current trading prices, LZAGF is priced at $635.20, while CLIFF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas CLIFF's P/E ratio is -1.76. In terms of profitability, LZAGF's ROE is +0.10%, compared to CLIFF's ROE of -0.12%. Regarding short-term risk, LZAGF is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check CLIFF's competition here
LZAGF vs LDDD Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, LDDD has a market cap of 15.3M. Regarding current trading prices, LZAGF is priced at $635.20, while LDDD trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas LDDD's P/E ratio is -51.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to LDDD's ROE of -0.28%. Regarding short-term risk, LZAGF is less volatile compared to LDDD. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check LDDD's competition here
LZAGF vs IZOZF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IZOZF has a market cap of 13.9M. Regarding current trading prices, LZAGF is priced at $635.20, while IZOZF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IZOZF's P/E ratio is -10.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to IZOZF's ROE of +0.48%. Regarding short-term risk, LZAGF is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IZOZF's competition here
LZAGF vs ABDXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ABDXF has a market cap of 13.3M. Regarding current trading prices, LZAGF is priced at $635.20, while ABDXF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, LZAGF's ROE is +0.10%, compared to ABDXF's ROE of -0.45%. Regarding short-term risk, LZAGF is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ABDXF's competition here
LZAGF vs IDXG Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IDXG has a market cap of 8.9M. Regarding current trading prices, LZAGF is priced at $635.20, while IDXG trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IDXG's P/E ratio is 2.25. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDXG's ROE of +4.85%. Regarding short-term risk, LZAGF is less volatile compared to IDXG. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IDXG's competition here
LZAGF vs MXDHF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MXDHF has a market cap of 8.6M. Regarding current trading prices, LZAGF is priced at $635.20, while MXDHF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, LZAGF's ROE is +0.10%, compared to MXDHF's ROE of +5.17%. Regarding short-term risk, LZAGF is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MXDHF's competition here
LZAGF vs JMPHF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, JMPHF has a market cap of 8.1M. Regarding current trading prices, LZAGF is priced at $635.20, while JMPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas JMPHF's P/E ratio is 4.28. In terms of profitability, LZAGF's ROE is +0.10%, compared to JMPHF's ROE of +0.31%. Regarding short-term risk, LZAGF is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check JMPHF's competition here
LZAGF vs IMMVF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IMMVF has a market cap of 6.1M. Regarding current trading prices, LZAGF is priced at $635.20, while IMMVF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IMMVF's P/E ratio is -0.50. In terms of profitability, LZAGF's ROE is +0.10%, compared to IMMVF's ROE of -5.64%. Regarding short-term risk, LZAGF is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IMMVF's competition here
LZAGF vs AVCRF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, AVCRF has a market cap of 6.1M. Regarding current trading prices, LZAGF is priced at $635.20, while AVCRF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas AVCRF's P/E ratio is -6.03. In terms of profitability, LZAGF's ROE is +0.10%, compared to AVCRF's ROE of -0.95%. Regarding short-term risk, LZAGF is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check AVCRF's competition here
LZAGF vs SQIDF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SQIDF has a market cap of 6.1M. Regarding current trading prices, LZAGF is priced at $635.20, while SQIDF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, LZAGF's ROE is +0.10%, compared to SQIDF's ROE of +4.47%. Regarding short-term risk, LZAGF is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SQIDF's competition here
LZAGF vs ICBU Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ICBU has a market cap of 5.4M. Regarding current trading prices, LZAGF is priced at $635.20, while ICBU trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ICBU's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ICBU's ROE of -0.22%. Regarding short-term risk, LZAGF is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ICBU's competition here
LZAGF vs PMSNF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, PMSNF has a market cap of 5.2M. Regarding current trading prices, LZAGF is priced at $635.20, while PMSNF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas PMSNF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to PMSNF's ROE of +0.34%. Regarding short-term risk, LZAGF is more volatile compared to PMSNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check PMSNF's competition here
LZAGF vs VRCDF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, VRCDF has a market cap of 4.5M. Regarding current trading prices, LZAGF is priced at $635.20, while VRCDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas VRCDF's P/E ratio is -0.10. In terms of profitability, LZAGF's ROE is +0.10%, compared to VRCDF's ROE of -1.93%. Regarding short-term risk, LZAGF is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check VRCDF's competition here
LZAGF vs RNVA Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, RNVA has a market cap of 4.3M. Regarding current trading prices, LZAGF is priced at $635.20, while RNVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas RNVA's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, LZAGF is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check RNVA's competition here
LZAGF vs TDSGF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, TDSGF has a market cap of 3.9M. Regarding current trading prices, LZAGF is priced at $635.20, while TDSGF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas TDSGF's P/E ratio is -3.90. In terms of profitability, LZAGF's ROE is +0.10%, compared to TDSGF's ROE of -9.19%. Regarding short-term risk, LZAGF is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check TDSGF's competition here
LZAGF vs ANPCF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ANPCF has a market cap of 3.4M. Regarding current trading prices, LZAGF is priced at $635.20, while ANPCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ANPCF's P/E ratio is -0.17. In terms of profitability, LZAGF's ROE is +0.10%, compared to ANPCF's ROE of -0.90%. Regarding short-term risk, LZAGF is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ANPCF's competition here
LZAGF vs IBXXF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IBXXF has a market cap of 2.2M. Regarding current trading prices, LZAGF is priced at $635.20, while IBXXF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IBXXF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to IBXXF's ROE of +1.43%. Regarding short-term risk, LZAGF is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IBXXF's competition here
LZAGF vs IVRO Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IVRO has a market cap of 1.8M. Regarding current trading prices, LZAGF is priced at $635.20, while IVRO trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IVRO's P/E ratio is -0.80. In terms of profitability, LZAGF's ROE is +0.10%, compared to IVRO's ROE of +0.06%. Regarding short-term risk, LZAGF is more volatile compared to IVRO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check IVRO's competition here
LZAGF vs CHHL Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, CHHL has a market cap of 1.8M. Regarding current trading prices, LZAGF is priced at $635.20, while CHHL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas CHHL's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CHHL's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check CHHL's competition here
LZAGF vs SLDX Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SLDX has a market cap of 1.6M. Regarding current trading prices, LZAGF is priced at $635.20, while SLDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SLDX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to SLDX's ROE of +0.17%. Regarding short-term risk, LZAGF is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SLDX's competition here
LZAGF vs DIGP Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, DIGP has a market cap of 1.1M. Regarding current trading prices, LZAGF is priced at $635.20, while DIGP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas DIGP's P/E ratio is -1.04. In terms of profitability, LZAGF's ROE is +0.10%, compared to DIGP's ROE of +1.19%. Regarding short-term risk, LZAGF is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check DIGP's competition here
LZAGF vs EPGNF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, EPGNF has a market cap of 982.2K. Regarding current trading prices, LZAGF is priced at $635.20, while EPGNF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas EPGNF's P/E ratio is -0.30. In terms of profitability, LZAGF's ROE is +0.10%, compared to EPGNF's ROE of +0.03%. Regarding short-term risk, LZAGF is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EPGNF's competition here
LZAGF vs RSHN Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, RSHN has a market cap of 857.6K. Regarding current trading prices, LZAGF is priced at $635.20, while RSHN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas RSHN's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, LZAGF is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check RSHN's competition here
LZAGF vs IDTA Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IDTA has a market cap of 708K. Regarding current trading prices, LZAGF is priced at $635.20, while IDTA trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IDTA's P/E ratio is 8.75. In terms of profitability, LZAGF's ROE is +0.10%, compared to IDTA's ROE of +0.13%. Regarding short-term risk, LZAGF is less volatile compared to IDTA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IDTA's competition here
LZAGF vs SZLSF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SZLSF has a market cap of 630K. Regarding current trading prices, LZAGF is priced at $635.20, while SZLSF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SZLSF's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.10%, compared to SZLSF's ROE of +4.82%. Regarding short-term risk, LZAGF is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check SZLSF's competition here
LZAGF vs SCRSF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, SCRSF has a market cap of 600.3K. Regarding current trading prices, LZAGF is priced at $635.20, while SCRSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas SCRSF's P/E ratio is -0.20. In terms of profitability, LZAGF's ROE is +0.10%, compared to SCRSF's ROE of +2.02%. Regarding short-term risk, LZAGF is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check SCRSF's competition here
LZAGF vs NSTM Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, NSTM has a market cap of 493.3K. Regarding current trading prices, LZAGF is priced at $635.20, while NSTM trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas NSTM's P/E ratio is 0.20. In terms of profitability, LZAGF's ROE is +0.10%, compared to NSTM's ROE of -0.83%. Regarding short-term risk, LZAGF is more volatile compared to NSTM. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check NSTM's competition here
LZAGF vs MBGNF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MBGNF has a market cap of 101.8K. Regarding current trading prices, LZAGF is priced at $635.20, while MBGNF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MBGNF's P/E ratio is -0.59. In terms of profitability, LZAGF's ROE is +0.10%, compared to MBGNF's ROE of +0.26%. Regarding short-term risk, LZAGF is less volatile compared to MBGNF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check MBGNF's competition here
LZAGF vs NVTAQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, NVTAQ has a market cap of 85.9K. Regarding current trading prices, LZAGF is priced at $635.20, while NVTAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to NVTAQ's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check NVTAQ's competition here
LZAGF vs ARYC Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ARYC has a market cap of 79.3K. Regarding current trading prices, LZAGF is priced at $635.20, while ARYC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ARYC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, LZAGF is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check ARYC's competition here
LZAGF vs HCLC Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, HCLC has a market cap of 74K. Regarding current trading prices, LZAGF is priced at $635.20, while HCLC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas HCLC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check HCLC's competition here
LZAGF vs MEDD Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MEDD has a market cap of 63.8K. Regarding current trading prices, LZAGF is priced at $635.20, while MEDD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MEDD's P/E ratio is -0.02. In terms of profitability, LZAGF's ROE is +0.10%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, LZAGF is less volatile compared to MEDD. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check MEDD's competition here
LZAGF vs IHTI Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, IHTI has a market cap of 32.5K. Regarding current trading prices, LZAGF is priced at $635.20, while IHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas IHTI's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check IHTI's competition here
LZAGF vs TOMDF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, TOMDF has a market cap of 14.1K. Regarding current trading prices, LZAGF is priced at $635.20, while TOMDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas TOMDF's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, LZAGF is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check TOMDF's competition here
LZAGF vs CGNH Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, CGNH has a market cap of 12K. Regarding current trading prices, LZAGF is priced at $635.20, while CGNH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas CGNH's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, LZAGF is more volatile compared to CGNH. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CGNH's competition here
LZAGF vs ABMC Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ABMC has a market cap of 4.8K. Regarding current trading prices, LZAGF is priced at $635.20, while ABMC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ABMC's P/E ratio is 0.01. In terms of profitability, LZAGF's ROE is +0.10%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, LZAGF is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ABMC's competition here
LZAGF vs CYPS Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, CYPS has a market cap of 4.1K. Regarding current trading prices, LZAGF is priced at $635.20, while CYPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas CYPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to CYPS's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to CYPS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check CYPS's competition here
LZAGF vs RGDXQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, RGDXQ has a market cap of 3.9K. Regarding current trading prices, LZAGF is priced at $635.20, while RGDXQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, LZAGF is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check RGDXQ's competition here
LZAGF vs DMTKQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, DMTKQ has a market cap of 3.5K. Regarding current trading prices, LZAGF is priced at $635.20, while DMTKQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas DMTKQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to DMTKQ's ROE of -1.06%. Regarding short-term risk, LZAGF is more volatile compared to DMTKQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check DMTKQ's competition here
LZAGF vs MEDVF Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MEDVF has a market cap of 2.7K. Regarding current trading prices, LZAGF is priced at $635.20, while MEDVF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MEDVF's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to MEDVF's ROE of +2.13%. Regarding short-term risk, LZAGF is less volatile compared to MEDVF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check MEDVF's competition here
LZAGF vs GWHP Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, GWHP has a market cap of 1.3K. Regarding current trading prices, LZAGF is priced at $635.20, while GWHP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas GWHP's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to GWHP's ROE of +6.19%. Regarding short-term risk, LZAGF is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check GWHP's competition here
LZAGF vs ROSGQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, ROSGQ has a market cap of 593. Regarding current trading prices, LZAGF is priced at $635.20, while ROSGQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to ROSGQ's ROE of -1.35%. Regarding short-term risk, LZAGF is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check ROSGQ's competition here
LZAGF vs BIOCQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BIOCQ has a market cap of 263. Regarding current trading prices, LZAGF is priced at $635.20, while BIOCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BIOCQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, LZAGF is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BIOCQ's competition here
LZAGF vs HTGMQ Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, HTGMQ has a market cap of 221. Regarding current trading prices, LZAGF is priced at $635.20, while HTGMQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, LZAGF is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check HTGMQ's competition here
LZAGF vs OPGX Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, OPGX has a market cap of 17. Regarding current trading prices, LZAGF is priced at $635.20, while OPGX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas OPGX's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.10%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, LZAGF is less volatile compared to OPGX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.Check OPGX's competition here
LZAGF vs BGNX Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, BGNX has a market cap of 0. Regarding current trading prices, LZAGF is priced at $635.20, while BGNX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas BGNX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to BGNX's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check BGNX's competition here
LZAGF vs AGHC Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, AGHC has a market cap of 0. Regarding current trading prices, LZAGF is priced at $635.20, while AGHC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas AGHC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, LZAGF is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check AGHC's competition here
LZAGF vs EPGNY Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, EPGNY has a market cap of 0. Regarding current trading prices, LZAGF is priced at $635.20, while EPGNY trades at $2.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, LZAGF's ROE is +0.10%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, LZAGF is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check EPGNY's competition here
LZAGF vs MRPS Comparison April 2026
LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LZAGF stands at 44.7B. In comparison, MRPS has a market cap of 0. Regarding current trading prices, LZAGF is priced at $635.20, while MRPS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LZAGF currently has a P/E ratio of 38.29, whereas MRPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.10%, compared to MRPS's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.Check MRPS's competition here